

## 1 **Supplementary methods**

2

3 **Plasmid and infection.** shRNAs were cloned into the pRSI-U6-(sh)-UbiC-TagRFP-2A-  
4 Puro vector (Cellecta Inc.) and used to infect cells to silence a neutral control Luc (5'-  
5 CAAATCACAGAATCGTTGTAT-3') or WDR5 (sh#1: 5'-CTGGTTACAAGTTGGGAATAT-  
6 3'; sh#2: 5'-GTGTCTGGCTTAGAGGATAAT-3'). Concentrated lentiviral particles from  
7 single plasmids were produced by transfecting 293T cells and added as shRNAs pool to  
8 cell lines and PDXs cultures, together with 4 µg/mL polybrene (Sigma) for 16 hours. After  
9 48 hours medium was replaced and 3 µg/mL of puromycin was added for 72 hours before  
10 performing the experiments. Cells were infected at high Multiplicity Of Infection (MOI) (Cell  
11 lines at MOI of ~3, and PDX culture cells at MOI of ~50). Over-expression vectors pHAGE-  
12 GFP\_IRES\_GFP or pHAGE-WDR5\_IRES\_GFP was obtained from MD Anderson Cancer  
13 Center (Texas). ShRNA sequences to silence TGFβ1 were extrapolated elsewhere [1] and  
14 cloned into pRSI-U6-(sh)-UbiC-TagGFP-2A-Puro vector (Cellecta Inc.). MCF10DCIS cells  
15 were transduced as indicated before.

16 ***In vitro* study.** Proliferation assay. 2000 MCF10DCIS cells *per* well were seeded in  
17 triplicate. Cell Titer Glo (Promega) was used to evaluate cells viability from day 0 to day 3  
18 after plating. Data are expressed as relative ratio of treated (shWDR5) and control cells  
19 (shLuc). FBS-directed migration assay. ShLuc and shWDR5 cells were seeded ( $2.5 \times 10^5$   
20 MCF10DCIS or PDXs cells in duplicate;  $5 \times 10^4$  MDA-MB-231 and MCF10A) in the upper  
21 chamber of 8.0 µm pore size inserts of 24-well plates. MCF10DCIS and MCF10A cells  
22 were resuspended in 0.5% horse serum, PDXs in 1% FBS, and complete medium  
23 supplemented with 50% FBS were added as chemoattractant in the lower chamber,  
24 instead MDA-MB-231 were starved overnight in 1% FBS and complete medium was  
25 added in the lower chamber. After 16 (MCF10DCIS and MDA-MB231) to 36 hours (PDXs)

26 of incubation, migrated cells were fixed and stained with 0.5% Crystal Violet. Migration  
27 was quantified by ImageJ analysis. Wound healing assay. MDA-MB-231 and MCF10DCIS  
28 cells were seeded on six-well plates and a scratch was introduced into a confluent  
29 monolayer with a pipette tip. To ensure that differences in cell migration were not due to  
30 differences in cell growth, cells were incubated overnight in serum-free medium prior to  
31 scratch injury. Images were taken immediately or at regular intervals until 24h (MDA-MB-  
32 231) or 48h (MCF10DCIS) from scratching. Cell migration rate was quantified by ImageJ  
33 as distance between migration front and closure of the wound. Live cell random migration  
34 assay.  $1.2 \times 10^4$  MCF10DCIS or MDA-MB-231 cells were plated in 12 well plates and time-  
35 lapse imaging of cell migration was performed on a Nikon Eclipse Ti microscope equipped  
36 with an incubator chamber maintained at 37°C in a 5% CO<sub>2</sub> atmosphere. Tracking of cells  
37 was performed using the Trackmate plugin distributed by Fiji software. Four random fields  
38 were acquired *per* well and about 200 cells were measured *per* group (acquisition every  
39 10' for 24h). The motility of cells for the two groups (shLuc and shWDR5) was considered  
40 by excluding cells' trajectory due to mitotic events.

41  
42 **Western blot.** Membranes were probed with the following antibodies: Vinculin (Sigma  
43 V9131), GAPDH (Cell Signaling #2118), Tubulin (Sigma Aldrich T9026), WDR5 (Cell  
44 Signaling #13105), Vimentin (Abcam), CDH1 [24E10] (Cell signaling), CDH2 [5D5]  
45 (Abcam), SNAI2 [C19G7] and SNAI1 [C15D3] (both from Cell Signaling), PCNA [M0879]  
46 (Dako), PARP (Cell Signaling) and  $\gamma$ H2AX (Biolegend).

47  
48 **Subcellular fractionation.** Subcellular fractionation in shLuc and shWDR5 MCF10DCIS  
49 cells was performed as indicated by supplier (Subcellular fractionation kit - Thermo  
50 Scientific).

51

52 **Immunohistochemistry.** Eleven normal mammary glands from patients and tumor  
53 fragments from eight PDXs were formalin-fixed and paraffin-embedded. After  
54 deparaffinization, sections were treated with citrate for 50 minutes at 95°C, followed by  
55 incubation with 3% hydrogen peroxide in distilled water for 5 minutes at RT. Sections were  
56 stained with WDR5 primary antibody (Cell Signaling #13105). Images were acquired by  
57 Olympus BX51 up-right (objective 40x) connected to Nikon Color Camera (software NIS-  
58 elements). Expression was quantified by using Fiji tools for DAB positivity. Statistical  
59 significance was determined using a Student *t* test.

60

61 **Cell cycle analysis.** MDA-MB-231 cells were treated with PTX (10 nM), OICR-9429 (20  
62 µM) or Galunisertib (10 µM) alone or in combination for 24 hours. Cells were pulsed with 5  
63 mM Bromodeoxyuridine (BrdU), fixed and stained against BrdU (BD Biosciences). Cells  
64 were stained with secondary antibody, incubated with propidium iodide (PI) and RNaseA  
65 and then acquired by fluorescent-activated cell sorting (FACS) at FACSCelesta (BD  
66 Bioscience). Analysis was performed using FlowJo 10.6 analysis software.

67

68 **RNA-sequencing.** Libraries were sequenced in multiplex at 50bp single reads on an  
69 Illumina HiSeq2000 (average sequence coverage ~40 million reads/sample). For PDXs,  
70 after quality filtering according to the Illumina pipeline, 50 bp single-end reads were  
71 aligned to the human (hg19) and mouse (mm10) reference genome using TopHat2  
72 (version 2.1.0) [2] with the option “--b2-very-sensitive”. After removing the reads aligned to  
73 the mouse genome, only uniquely mapped reads were retained. Alignment to the hg19  
74 human genome was performed on MCF10DCIS cells. At gene level, expression counts  
75 were estimated using featureCounts (Rsubread version 1.5.1) [3], summarized across all

76 exons as annotated in the *Homo sapiens* transcriptome (NCBI build 37.2), with default  
77 options. Both coding and long noncoding RNA genes were retained for downstream  
78 analyses. Normalization and identification of differentially expressed genes in three  
79 biological replicates of shLuc control and in shWDR5 for each PDX or in the MCF10DCIS  
80 cancer cell line, were carried out using EdgeR R-package (version 3.2.2) [4]. Prior to  
81 normalization using the Trimmed Mean of M (TMM) method, genes whose expression was  
82 lower than 0.1 Count Per Million (0.5 for the MCF10DCIS) in more than three samples  
83 were filtered out. A common dispersion was estimated for all genes to measure the global  
84 biological variation (with option *robust = "TRUE"*). A negative binomial generalized log-  
85 linear model was fitted to each gene, and likelihood ratio tests were performed to assess  
86 differential expression in pairwise analyses for each PDX [5]. The expression levels were  
87 calculated using the reads per kilobase per million reads method (RPKM). Genes were  
88 identified as differentially expressed (DEGs) when the following criteria were met:  $\log_2$   
89 fold-change (FC)  $\geq 10.61$ , false discovery rate (FDR)  $< 0.05$  and expression  $> 0.5$  RPKM  
90 (1 RPKM in the MCF10DCIS cell line) in all sample in at least one condition. 253 genes  
91 (161 down- and 92 up-regulated) were commonly deregulated in at least 2 comparisons.  
92 This set was used in the functional category enrichment analyses.

93 DEGs in PDX samples were hierarchically clustered using pheatmap R package [Kolde R:  
94 pheatmap: Pretty Heatmaps 2015. <https://CRAN.R-project.org/package=pheatmap>]  
95 utilizing a Euclidean distance metric and complete linkage rule, after removing batch  
96 effects across PDX, setting the minimum RPKM value to 0.1 and  $\log_2$ -transformation.  
97 DEGs were analyzed using Ingenuity Pathway Analysis (IPA,  
98 Ingenuity® Systems, [www.ingenuity.com](http://www.ingenuity.com); Redwood City, CA) and Gene Ontology term  
99 enrichment using DAVID tool (version 6.8 Beta) [6].

100

101 **ChIP-sequencing.** Reads were mapped to the human hg19 reference genome using  
102 Bowtie2 v2.2.6 [7] with the “*–very-sensitive*” preset of parameters. Reads that did not align  
103 to the nuclear genome or that aligned to the mitochondrial genome were removed.  
104 Moreover, duplicate reads were marked and removed using SAMtools [8]. Peak calling for  
105 WDR5 ChIP-seq was performed using MACS2 (version 2.1.0.20150731) [9] using the “*--*  
106 *nomodel*”, “*--extsize 200*” and “*--pvalue 0.001*” flags and arguments. Peaks with a *P*-value  
107 > 1E-3, both in the comparison ChIP vs. input DNA and ChIP vs. ChIP, and those  
108 blacklisted by the ENCODE consortium analysis of artefactual signals in human genome  
109 (<https://sites.google.com/site/anshulkundaje/projects/blacklists>) were removed using  
110 bedtools [10]. The annotatePeaks script from the HOMER package [11] was used to  
111 identify the genomic location of WDR5 peaks and assign them to the nearest transcription  
112 start site (TSS). Then we classified each peak as either TSS-proximal or TSS-distal,  
113 depending on its distance (< or > +/-3 kb, respectively) from TSS.

114 The H3K4me3 ChIP-seq of shLuc control and shWDR5 in MCF10DCIS cancer cell line  
115 were aligned as above. Then, we extracted reads mapped to a regions of ±1’500 bp  
116 relative to TSS for all annotated transcripts (NCBI build 37.2) using the coverageBed tool  
117 in bedtools [10].

118 We applied RPM normalization to all datasets and tracks for visualization in the Integrative  
119 Genomics Viewer (IGV) [12] were generated using bedGraphToBigWig tool.

120

121 **ChIP Quantitative PCR.** Real-time PCR and primers specific to the promoter of TGFβ1  
122 (5’-3’. FW: CTTCTCCAGCCAGTTTCTT; RV: TCACCCGCGTGCTAATG) were used to  
123 determine TGFβ1 binding to the immunoprecipitated DNA with WDR5 antibody. AchR  
124 (acetylcholine receptor) was used as negative control. The intensity was normalized with  
125 respect to the Input (no immunoprecipitation).

126 **References**

- 127 1. Oh S, Kim E, Kang D, Kim M, Kim JH, Song JJ. Transforming growth factor-beta  
128 gene silencing using adenovirus expressing TGF-beta1 or TGF-beta2 shRNA. *Cancer*  
129 *gene therapy*. 2013;**20**(2):94-100.
- 130 2. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate  
131 alignment of transcriptomes in the presence of insertions, deletions and gene fusions.  
132 *Genome biology*. 2013;**14**(4):R36.
- 133 3. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for  
134 assigning sequence reads to genomic features. *Bioinformatics* (Oxford, England).  
135 2014;**30**(7):923-30.
- 136 4. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for  
137 differential expression analysis of digital gene expression data. *Bioinformatics* (Oxford,  
138 England). 2010;**26**(1):139-40.
- 139 5. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global  
140 reference for human genetic variation. *Nature*. 2015;**526**(7571):68-74.
- 141 6. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The  
142 DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to  
143 functionally analyze large gene lists. *Genome biology*. 2007;**8**(9):R183.
- 144 7. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nature*  
145 *methods*. 2012;**9**(4):357-9.
- 146 8. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence  
147 Alignment/Map format and SAMtools. *Bioinformatics* (Oxford, England). 2009;**25**(16):2078-  
148 9.
- 149 9. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-  
150 based analysis of ChIP-Seq (MACS). *Genome biology*. 2008;**9**(9):R137.

- 151 10. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic  
152 features. *Bioinformatics (Oxford, England)*. 2010;**26**(6):841-2.
- 153 11. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple  
154 combinations of lineage-determining transcription factors prime cis-regulatory elements  
155 required for macrophage and B cell identities. *Molecular cell*. 2010;**38**(4):576-89.
- 156 12. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al.  
157 Integrative genomics viewer. *Nature biotechnology*. 2011;**29**(1):24-6.
- 158